Citations

Mayo Clinic

Showing 10 of 108162 citations.

Shifting Patterns of Colorectal Cancer Burden in the United States (1999–2023): Implications for Precision Medicine Strategies and Drug Resistance in Early-Onset Colorectal Cancer
Sun, C J , Liu, Li , Lees, Elizabeth , Billstein, Laura , Zou, Yuntao , Fickel, Abigail, Yan, Yan , Wang, Yichen, Vinh, Tuan, Travers, paul, Kumbhari, Vivek , Huang, Yuting , Travers, Paul , Lees, Elizabeth H , Billstein, Laura E, Travers, Paul M , Huang, Yuting , Yan, Yan , Fickel, Abigail

Cancers | May 29, 2026 | Volume: 18 | Issue: 11 | Pages: 1768

10.3390/cancers18111768 | PMID 42279351 Get It

Background: Colorectal cancer (CRC) remains one of the common causes of cancer-related morbidity and mortality in the United States. Emerging increases in early-onset CRC and persistent disparities remain major public health concerns. Objective: To characterize long-term CRC incidence and mortality trends in the United States, with particular emphasis on identifying demographic groups experiencing rising or plateauing disease burden. Methods: We conducted a population-based ecological study using CRC incidence data from the United States Cancer Statistics database (1999–2022) and mortality data from CDC WONDER (1999–2023). Temporal trends were evaluated using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC), stratified by age, sex, race/ethnicity, and urbanization level. Results: Overall CRC incidence and mortality declined during the study period (both AAPC approximately −2.08%). However, incidence increased significantly among adults younger than 55 years, particularly those aged 20–24 years. Mortality also increased among younger adults aged 25–44 years and remained elevated among individuals aged 45–54 years. Non-Hispanic Black individuals consistently experienced the highest incidence and mortality rates. Mortality declines plateaued in several older age groups after 2018–2020. Conclusions: Despite overall improvements in CRC burden, increasing incidence and mortality among younger adults and persistent disparities highlight the need for risk-stratified prevention, earlier detection strategies, and tailored therapeutic approaches.
Are you still engaged? Leveraging the LMS to support engagement in asynchronous courses
Florio, Damian N. Di, Nelson, Kristina B. , Jimison, Ryan C. , Dierkhising, Ross , Silvano, Carmen J., Enders, Felicity , Enders, Felicity T , Florio, Damian N. Di

Journal of Clinical and Translational Science | May 29, 2026 | Volume: 10 | Issue: 1 | Pages: No page available

10.1017/cts.2026.10752 | PMID 42375225 Get It

Abstract Introduction: Asynchronous online courses are plagued with the challenge of engaging students consistently. Behavioral interventions, such as bottlenecks (enforced deadlines) and nudges (automated reminders), may modulate behaviors that lead to engagement and can now be easily applied and measured in a Learning Management System (LMS). Methods: This study included three groups of three asynchronous online courses each over three academic quarters. Two distinct behavioral interventions, bottlenecks and nudges, were implemented to increase engagement with the course compared to non-intervention controls. Results: The results showed that behavioral intervention tools increase student engagement with course materials by measures of increased student access to the course and reduced time to quiz completion. However, there was no significant impact in grades across the three groups. Conclusion: The use of nudges and bottlenecks as behavioral interventions to increase engagement in asynchronous courses for Clinical and Translational Science Education is recommended as part of best practice in course design with the same or similar structure.
The Potential for Delay in Coordinated Care of Complex Patients Receiving Mohs Micrographic Surgery Due to GLP-1 Receptor Agonists
Lin, Raymond J., Vidal, Nahid Y. , Kim, Yong-Hun

Dermatologic Surgery | May 29, 2026 | Volume: 52 | Issue: 6S | Pages: S61-S62

10.1097/dss.0000000000005149 | PMID 42210889 Get It

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Cutaneous Biology: Implications for Skin Disease and Longevity
Vyas, Krishna, Gopinath, Shilpa , Dacso, Mara, Wyles, Saranya, Dacso, Mara M. , Green, Jeremy B. , Wyles, Saranya P.

Dermatologic Surgery | May 29, 2026 | Volume: 52 | Issue: 6S | Pages: S45-S54

10.1097/dss.0000000000005187 | PMID 42210887 Get It

BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have expanded from metabolic therapeutics to agents with broad effects on inflammation, tissue repair, cutaneous and adipose biology, and aging-related pathways. Clinicians increasingly encounter cutaneous manifestations and aesthetic sequelae with important implications for dermatologic counseling and multidisciplinary care. OBJECTIVE To review current evidence regarding GLP-1RA effects on skin biology, inflammatory dermatoses, wound healing, cutaneous adverse events, and aesthetic aging. MATERIALS AND METHODS A narrative review of clinical, translational, and mechanistic literature was performed, emphasizing psoriasis, hidradenitis suppurativa, wound repair, skin hypersensitivity reactions, autoimmune blistering disease, and facial volume loss associated with pharmacologic weight reduction. RESULTS GLP-1RAs are hypothesized to improve inflammatory skin conditions and wound repair through anti-inflammatory, immunometabolic, and proreparative pathways. Yet, their use may also be associated with injection-site reactions, hypersensitivity eruptions, rare autoimmune blistering disorders, and clinically significant facial deflation and skin laxity. Current evidence is strongest for mechanistic plausibility and observational clinical signals, whereas dermatology-specific randomized trials remain limited. CONCLUSION GLP-1RAs exert bidirectional effects on cutaneous biology. Recognition of both therapeutic opportunities and potential aesthetic or adverse sequelae is important, with patient counseling ideally occurring within a multidisciplinary framework that integrates metabolic benefits with skin health and appearance.
Reduced Epidermal p21 Expression Is Identified in Some Subjects on Systemic GLP-1 Receptor Agonists: A Hypothesis-Generating Pilot Study of Metabolic Modulation in Human Skin Senescence
Wyles, Saranya, Gopinath, Shilpa , Lynn, Brock , Pfizenmaier, Zachary, Ozarslan, Bengisu , Purushothaman, K‐Raman , Wyles, Saranya P.

Dermatologic Surgery | May 29, 2026 | Volume: 52 | Issue: 6S | Pages: S29-S34

10.1097/dss.0000000000005186 | PMID 42210884 Get It

BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1RAs) exert systemic metabolic and anti-inflammatory effects that may be relevant to cellular senescence, a key driver of skin aging. However, human cutaneous data are lacking. OBJECTIVE To explore whether systemic GLP-1RA therapy translates to a detectable reduction in cutaneous senescence, quantified by epidermal p21 expression and supported by AI-driven facial imaging. MATERIALS AND METHODS In this controlled observational pilot study, 3 male adults (GLP-1RA n = 2; GLP-1RA–naïve control n = 1) underwent 3-mm punch biopsies from a standardized, sun-protected gluteal site to isolate intrinsic aging. Senescence was quantified through blinded whole-epidermis digital annotation of p21-positive nuclei. Clinical phenotypes were assessed using noninvasive cheek measurements and AI-based facial age estimation. RESULTS The cohort demonstrated divergence in senescence-associated biomarkers correlating with GLP-1RA exposure. The GLP-1RA–naïve control exhibited 8.0% ( n = 2,062 nuclei) epidermal senescence. By contrast, participants with 163 and 62 days of GLP-1RA exposure showed reduced senescence burdens of 2.4% ( n = 2,045) and 0.6% ( n = 1,636), respectively. Automated facial age estimation remained concordant with chronological age across subjects. CONCLUSION Systemic GLP-1RA exposure is associated with a substantial reduction in epidermal p21 expression in some subjects, suggesting a senomorphic effect and supporting further mechanistic studies at the interface of metabolic regulation and skin aging.
‘Medical Haematology’ via systems‐based haematology
Godby, Richard , May, Jori, Godby, Richard Curtis , May, Jori E.

British Journal of Haematology | May 29, 2026 | Volume: 209 | Issue: 2 | Pages: 851-852

10.1111/bjh.70590 | PMID 42212357 Get It

Management of Central Disorders of Hypersomnolence in Pregnancy and Lactation
Bernard, Matthew E., Jegen, Dominika , Furst, Joseph W. , Mansukhani, Meghna P., Abideen, Zain Ul, Kolla, Bhanu Prakash , Abideen, Zain Ul , Mansukhani, Meghna P.

Journal of Primary Care & Community Health | May 29, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/21501319261456031 | PMID 42212348 Get It

Over 37% of pregnant women report excessive daytime sleepiness or hypersomnia during the first trimester, and commonly throughout the remaining trimesters of pregnancy and the postpartum period. The clinical presentation and symptoms of central disorders of hypersomnolence (CDH) such as narcolepsy, idiopathic hypersomnia, or excessive daytime sleepiness secondary to shift work or obstructive sleep apnea may be confounded by physiological changes in sleep architecture and hormonal fluctuations occurring during pregnancy. These overlapping features may cause delays in diagnosis and treatment, impacting quality of life, maternal functioning, and overall health. Management of CDH during pregnancy and lactation requires careful consideration of maternal benefits, potential side effects of medications and fetal and neonatal safety. Here, we present a case of idiopathic hypersomnia and detail management and outcomes during pregnancy and lactation. We briefly review the existing literature on prevalence, pathophysiological mechanisms, diagnostic challenges, objective findings, and risks posed by CDH in pregnancy and lactation. In this narrative review for primary care clinicians, we also summarize currently available evidence regarding the efficacy, teratogenic and other risks of pharmacologic agents used in the treatment of CDH in pregnancy and lactation. Lastly, we provide a clinical algorithm for management of CDH during pregnancy and lactation.
Characterisation of the Novel HLA‐DPA1*03:25 Allele by Next Generation Sequencing
Merschman, Jarret , Barnes, Rachel, Wakefield, Laurie, Kreuter, Justin, Gandhi, Manish J. , Gandhi, Manish , Wakefield, Laurie L., Kreuter, Justin D.

HLA | May 29, 2026 | Volume: 107 | Issue: 6 | Pages: No page available

10.1111/tan.70773 | PMID 42210829 Get It

ABSTRACT HLA‐DPA1*03:25 is characterised by a single nucleotide substitution in codon 96 in exon 3.
Embracing technology to improve peripheral intravenous access and care: A consensus statement from vascular access experts and patients
Spencer, Timothy R. , Strain, Barbara, Hadaway, Lynn, Schears, Gregory, Steere, Lee, Hopkins, Thomas, Weathers, Elizabeth , Hadaway, Lynn

The Journal of Vascular Access | May 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/11297298261451300 | PMID 42210772 Get It

Background/objectives: To develop expert consensus on peripheral venous access devices (PVAD) and associated care practices, and to formulate guidance recommendations aimed at improving peripheral venous access and management, including the integration of vein visualization technology. This is particularly important for patient populations with peripheral venous depletion, who often present with compromised vasculature that complicates successful PVAD access and increases the risk of complications. Preserving vascular integrity in these patients is essential for maintaining treatment pathways and preventing long-term vascular damage. Methods: A multi-phase approach to consensus development was used consisting of the following: (1) a literature review, (2) a survey and consultation with a vascular access expert panel ( n = 9), and (3) a consultation meeting with patient and public representatives ( n = 2). Results: Survey results and consultation findings from the expert panel demonstrated consensus for 14 of 24 statements. Further analysis resulted in a total of four key problem statements on peripheral venous access and care, and 11 recommendations for future development. Following review by patient and public representatives, three additional recommendations were added, and three existing recommendations were refined. The final consensus statement reflects four problem statements with 14 recommendations. Conclusion: This expert consensus presents 14 evidence-informed statements designed to strengthen practice, improve patient safety, and enhance clinician confidence and competence. Central to these recommendations is the adoption of routine structured pre-insertion vessel assessment using vein visualization technology where appropriate to minimize vessel trauma, and promote more consistent, high-quality vascular access care.
Age-specific early-life gut microbiome associations with eczema and food allergies during early immune development
Núñez, Harold, Straub, Timothy J. , Imam, Nabeel, Goad, David, Mueller, Noel T., Hoy, Cheryl Sew, Paullin, Trillitye, Sukhum, Kimberley V., Mars, Ruben A T, Goad, David, Mars, Ruben A. , Paullin, Trillitye R. , Sukhum, Kimberley V.

Frontiers in Microbiomes | May 29, 2026 | Volume: 5 | Issue: No issue available | Pages: No page available

10.3389/frmbi.2026.1804117 | PMID 42293161 Get It

Introduction Eczema and food allergy commonly emerge during infancy and are linked to changes in the gut microbiome, yet it remains unclear when microbiome differences associated with allergic disease first appear during development. Methods We analyzed age-stratified shotgun metagenomic data from 97 children aged 4–36 months, including physician-confirmed cases of eczema or food allergy and non-allergic controls, excluding recent antibiotic or probiotic exposure. Microbial taxa, functional pathways, and composite microbiome metrics were evaluated across three developmental stages: early infancy (4–6 months), mid-infancy (6–12 months), and toddlerhood (12–36 months). Results Differences between allergic and non-allergic children were minimal before 6 months of age but became more apparent during mid-infancy and persisted into toddlerhood. Allergic conditions were associated with reduced abundance of fiber-fermenting and butyrate-producing taxa, enrichment of facultative and inflammation-associated microbes, lower microbiome maturation scores, and shifts in metabolic and inflammatory functional capacity. Discussion These findings suggest that gut microbiome divergence associated with allergic disease becomes more apparent during mid-infancy, highlighting a developmentally relevant period for understanding early immune disruption. The results support further longitudinal and interventional studies aimed at clarifying whether earlier microbiome-targeted strategies may help modify progression along the atopic march.